alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
['G1202R'],"[{'ncitCode': 'C113655', 'drugName': 'Lorlatinib'}]",[],LEVEL_2,LEVEL_Fda2,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['30892989'],[],"Lorlatinib is an orally available, small molecule multi-targeted kinase inhibitor that is FDA-approved for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease, alectinib as the first ALK inhibitor therapy for metastatic disease or ceritinib as the first ALK inhibitor therapy for metastatic disease. The NCCN Non-Small Cell Lung Cancer Guidelines (V5.2024) lists lorlatinib for the treatment of patients with ALK-positive NSCLC with ALK G1202R or ALK L1196M, excluding tumors harboring both ALK G1202R and L1196M as compound mutations. In the Phase II study of lorlatinib in patients with ALK-positive NSCLC harboring ALK resistance mutations, patients harboring ALK G1202R/del (n=27, ALK G1202R; n=1, ALK G1202del) demonstrated an overall response rate of 57% (95% CI=37-76), a median duration of response of seven months (95% CI=6.1-NR) and a median progression-free survival of 8.2 months (95% CI=5.6-25.6) (PMID: 30892989)."
['G1202R'],"[{'ncitCode': 'C188054', 'drugName': 'NVL-655'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['39269178'],"[{'link': 'https://www.annalsofoncology.org/article/S0923-7534(24)02829-1/fulltext', 'abstract': 'Drilon, A. et al., Abstract# 1253O, ESMO 2024.'}]","NVL-655 is an orally available, small molecule ALK inhibitor. There are promising clinical data of response to NVL-655 in patients with ALK G1202R-mutated non-small cell lung cancer (NSCLC). In the Phase I/II ALKOVE-1 (NCT05384626) trial of NVL-655 in 32 patients with ALK-rearranged NSCLC harboring ALK G1202R single or compound mutations, the overall response rate (ORR) was 69% (22/32) (Abstract: Drilon, A. et al., Abstract# 1253O, ESMO 2024. https://www.annalsofoncology.org/article/S0923-7534(24)02829-1/fulltext). Of patients that were previously treated with lorlatinib (n=30) or were lorlatinib-na√Øve (n=2), the ORR was 67% (20/30) and 100% (2/2), respectively (Abstract: Drilon, A. et al., Abstract# 1253O, ESMO 2024. https://www.annalsofoncology.org/article/S0923-7534(24)02829-1/fulltext). In vivo studies with ALK-fusion positive xenograft models expressing ALK resistance mutations (ALK G1202R, G1202R/L1196M, G1202R/G1269A and G1202R/L1198F) demonstrated sensitivity to NVL-655 as measured by reduced tumor size and prolonged survival (PMID: 39269178)."
['G1202R'],"[{'ncitCode': 'C101790', 'drugName': 'Alectinib'}]",[],LEVEL_R2,LEVEL_Fda3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['29650534', '27130468', '27432227', '29376144', '24736079', '29373100']",[],"Alectinib is a second-generation small molecule inhibitor of ALK. Across various studies, patients with ALK fusion-positive non-small cell lung cancer (NSCLC) have acquired ALK G1202R mutations upon disease progression with alectinib treatment (PMID: 29373100, 29376144, 24736079, 27432227, 27130468). In a longitudinal study of 22 ALK-positive patients with NSCLC who progressed on ALK tyrosine kinase inhibitors (TKIs), five patients had ALK G1202R mutations upon disease progression with alectinib (PMID: 29376144). A separate study of resistance to ALK TKIs identified five patients with ALK-positive NSCLC who had a G1202R mutation upon progression with alectinib (PMID: 27432227). Additionally, case reports of resistance to second-generation ALK TKIs revealed G1202R as a mechanism of resistance to alectinib in two other patients (PMID: 24736079, 27130468). In vitro studies have demonstrated that alectinib fails to inhibit G1202R-mutant ALK at a clinically-achievable IC50 (PMID: 29650534)."
['G1202R'],"[{'ncitCode': 'C74061', 'drugName': 'Crizotinib'}]",[],LEVEL_R2,LEVEL_Fda3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['26698910', '25727400', '22277784', '31585938']",[],"Crizotinib is an orally available, small molecule multitarget kinase inhibitor that is FDA-approved for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ALK or ROS1-positive, as detected by an FDA-approved test. ALK-rearrangement for treatment with crizotinib were detected by the Vysis ALK Break Apart FISH Probe Kit or FoundationOne CDx. ALK G1202R has been identified as an acquired resistance mutation in patients with ALK-positive NSCLC upon disease progression with crizotinib treatment. In a clinical study, one patient with ALK-positive NSCLC was treated with crizotinib and acquired ALK G1202R and KIT amplification upon disease progression (PMID: 22277784). In a second clinical study, one patient with ALK-positive lung adenocarcinoma was treated with crizotinib and acquired ALK G1202R and E1154K upon disease progression (PMID: 31585938). Preclinical studies of ALK G1202R expressed in ALK-positive Ba/F3 cells demonstrate resistance to crizotinib as measured by increased IC50 values and sustained cellular proliferation following treatment (PMID: 25727400, 26698910)."
['G1202R'],"[{'ncitCode': 'C115112', 'drugName': 'Ceritinib'}]",[],LEVEL_R2,LEVEL_Fda3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['26698910', '25727400', '31358542', '27432227', '24675041']",[],"Ceritinib is an orally available, small molecule ALK inhibitor that is FDA-approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ALK-positive, as detected by an FDA-approved test. ALK rearrangement for treatment with ceritinib were detected by the FoundationOne CDx or the Ventana ALK (D5F3) CDx Assay. ALK G1202R has been identified as an acquired resistance mutation in patients with ALK-positive NSCLC upon disease progression with ceritinib treatment. In a retrospective clinical study, four patients with ALK-positive NSCLC were treated with ceritinib and acquired ALK G1202R upon disease progression (PMID: 31358542). In a clinical study, one patient with ALK-positive NSCLC with ALK G1269A and one patient with ALK-positive NSCLC with ALK S1206Y were treated with ceritinib and both patients acquired ALK G1202R upon disease progression (PMID: 24675041). In another clinical study, five patients with ALK-positive NSCLC were treated with ceritinib and acquired ALK G1202R upon disease progression, with one patient additionally acquiring ALK F1174L (PMID: 27432227). Preclinical studies of ALK G1202R expressed in ALK-positive Ba/F3 cells demonstrate resistance to ceritinib as measured by increased IC50 values and sustained cellular proliferation following treatment (PMID: 24675041, 25727400, 26698910)."
['G1202R'],"[{'ncitCode': 'C98831', 'drugName': 'Brigatinib'}]",[],LEVEL_R2,LEVEL_Fda3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],"['29935304', '31358542', '27432227']",[],"Brigatinib is an orally available, small molecule ALK inhibitor that is FDA-approved for the treatment of adult patients with ALK-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. ALK-rearrangements for treatment with brigatinib were detected by the Vysis ALK Break Apart FISH Probe Kit. ALK G1202R has been identified as an acquired resistance mutation in patients with ALK-positive NSCLC upon disease progression with brigatinib treatment. In a retrospective clinical study, three patients with ALK-positive NSCLC were treated with brigatinib and acquired ALK G1202R upon disease progression (PMID: 31358542). In a multicenter study, one patient with ALK-positive NSCLC and one patient with ALK-positive NSCLC with ALK V1180L were treated with brigatinib and acquired ALK G1202R upon disease progression, with one patient additionally acquiring ALK L1196M (PMID: 29935304). In a clinical study, three patients with ALK-positive lung adenocarcinoma were treated with brigatinib and acquired ALK G1202R upon disease progression (PMID: 27432227). Preclinical studies of ALK G1202R expressed in ALK-positive Ba/F3 cells demonstrate resistance to brigatinib as measured by increased IC50 values compared to wildtype (PMID: 27432227)."
